

## ・ 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Munetsugu T, Igawa K, Fujimoto T, Shibama S, Nishizawa A, Yokozeki H.	Cold-induced hyperhidrosis: possible association with hyper-IgE syndrome.	Int J Dermatol.		doi: 10.1111/1/ijd.13357.	2016 Oct 25.
Kato K, Namiki T, Yokozeki H.	Acquired anhidrosis in a case of autoimmune autonomic ganglionopathy.	J Dermatol.		doi: 10.1111/1/1346-8138.13655.	2016 Oct 24.
Munetsugu T, Fujimoto T, Oshima Y, Sano K, Murota H, Satoh T, Iwase S, Asahina M, Nakazato Y, Yokozeki H.	Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan.	J Dermatol.		doi: 10.1111/1/1346-8138.13649.	2016 Oct 24.
Tanese K, Niizeki H, Seki A, Nakabayashi K, Nakazawa S, Tokura Y, Kawashima Y, Kubo A, Ishiko A	Infiltration of mast cells in pachydermia of pachydermoperiostosis.	J Dermatol.		doi: 10.1111/1/1346-8138.13770.	2017 Feb 13.
杉本 佐江子, 佐田 憲映, 新関 寛徳, 中林 一彦, 岩月 啓氏	【遺伝子検索を行った皮膚病】<臨床例>SLCO2A1遺伝子ヘテロ複合型変異が同定された肥厚性皮膚骨膜炎.	皮膚病診療	38:	813-816	2016.08
Nakazawa S, Mori T, Niizeki H, Matsuda M, Nakabayashi K, Tokura Y	Complete type of pachydermoperiostosis with a novel mutation c.510G>A of the SLCO2A1 gene.	J Dermatol.		doi: 10.1111/1/1346-8138.13728.	2016 Dec 27
Fujiyama T, Ito T, Umayahara T, Ikeya S, Tatsuno K, Funakoshi A, Hashizume H, Tokura Y	Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion.	J Allergy Clin Immunol	138	517-528.e5	2016

Terao C, Yoshifuji H, Nakajima T, Yukawa N, Matsuda F, Mimori T	Ustekinumab as a therapeutic option for Takayasu arteritis: From genetic findings to clinical application.	Scand J Rheumatol.	45(1-2)	80-82	2016
Nakashima R, Hosono Y, Mimori T	Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease.	Lupus	25(8):	925-933	2016
Sato S, Murakami A, Kuwait A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M, Kuwana M	Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.	PLoS One.	11(4)	e0154285	2016
Okada Y, Mimori T, et al. ( 29 人中 22 番 目 )	Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis.	Am J Hum Genet.	99(2)	366-374	2016
Terao C, Yoshifuji H, Yamano Y, Kojima H, Yurugi K, Miura Y, Maekawa T, Handa H, Ohmura K, Saji H, Mimori T, Matsuda F	Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases.	Rheumatology (Oxford).	55(9)	1686-1692	2016
小林 拓, 梅野淳嗣, 久松理一, 江崎幹宏, 松井敏幸, 松本主之, 日比紀文 .	非特異性多発性小腸潰瘍症の難病指定と SLC20A1 関連小腸症 .	日本消化器病学会雑誌	113(8)	1380 -1385	2016

久松理一	特集/小腸潰瘍発症メカニズムはどこまで明らかになったか．SLCO2A1 の機能とプロスタグランジン関連腸症．	先端医学社 GI Research	第 24 巻 5 号	p28-33	2016
梅野淳嗣， 江崎幹宏， 久松理一， 河内修司， 蔵原晃一， 安川重義， 平井郁仁， 松井敏幸， 八尾恒良， 北園孝成， 松本主之	特集/小腸潰瘍発症メカニズムはどこまで明らかになったか．非特異性多発性小腸潰瘍症（CEAS）の発症メカニズム	先端医学社 GI Research	第 24 巻 5 号	p20-27	2016
Kogame T, Nomura T, Kataoka T, Hirata M, Ueshima C, Matsui M, Kabashima K.	Possible inducible skin-associated lymphoid tissues (iSALT)-like structures with CXCL13(+) fibroblast-like cells in secondary syphilis.	Br J Dermatol.	Epub ahead of print		2017
Egawa G, Kabashima K.	Visualization of the T Cell Response in Contact Hypersensitivity.	Methods Mol Biol.	Epub ahead of print		2017
Ewald DA, Noda S, Oliva M, Litman T, Nakajima S, Li X, Xu H, Workman CT, Scheipers P, Svitacheva N, Labuda T, Krueger JG, Suárez-Fariñas M, Kabashima K, Guttman-Yassky E.	Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling.	J Allergy Clin Immunol.	139(2)	562-571	2017
Nomura T, Katoh M, Yamamoto Y, Miyachi Y, Kabashima K.	Eosinophilic pustular folliculitis: A proposal of diagnostic and therapeutic algorithms.	J Dermatol.	43(11)	1301-1306	2016

Amano W, Nakajima S, Yamamoto Y, Tanimoto A, Matsushita M, Miyachi Y, <u>Kabashima K.</u>	JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.	J Dermatol Sci.	84(3)	258-265	2016
Nomura T, Katoh M, Yamamoto Y, Miyachi Y, <u>Kabashima K.</u>	Eosinophilic pustular folliculitis: Trends in therapeutic options.	J Dermatol.	43(7)	847-9	2016
Nomura T, Katoh M, Yamamoto Y, Miyachi Y, <u>Kabashima K.</u>	Eosinophilic pustular folliculitis: A published work-based comprehensive analysis of therapeutic responsiveness.	J Dermatol.	43(8)	919-27	2016

#### IV . 研究成果の刊行物・別刷

LETTER TO THE EDITOR

Infiltration of mast cells in pachydermia of pachydermoperiostosis

Dear Editor,

Pachydermoperiostosis (PDP; Online Mendelian Inheritance in Man #614441) is a rare hereditary disease characterized by distinctive digital clubbing, periostosis and pachydermia.<sup>1</sup> Patients

with PDP harbor homozygous mutations in the solute carrier organic anion transporter family member 2A1 gene (*SLCO2A1*) or the 15-hydroxyprostaglandin dehydrogenase gene (*HPPGD*), resulting in elevated prostaglandin E2 (PGE2) levels.<sup>1</sup>




Figure 1. (a) Representative clinical features of the forehead. Moderate pachydermia was noted in the forehead of patient 1. (b) Representative histopathological features of pachydermia (hematoxylin-eosin, original magnification 94). This specimen was obtained from the forehead of patient 1. Dermal edema, fibrosis and sebaceous hyperplasia were noted. (c) High-powered view at 9200. Infiltration of mast cells was noted (yellow arrowheads). (d) Immunohistochemical analysis of pachydermia sample for c-Kit staining (94). The sample was obtained from the forehead of patient 1. Prominent infiltration of c-Kit-positive cells was noted in the dermis. (e) Immunohistochemical analysis of normal forehead skin with c-Kit staining (94). This specimen was obtained from the area surrounding a benign tumor and used as a control. (f) Score of the c-Kit-positive cells in the dermis. Dermal c-Kit-positive cells from five different randomly selected areas in the dermis were counted using a high-powered field (HPF, 9400), and the average of the five sums was calculated. The number of c-Kit-positive cells in the dermis was increased in the pachydermia samples approximately three- to eightfold compared with controls.

Correspondence: Hironori Niizeki, M.D., Ph.D., Department of Dermatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. Email: niizeki-h@ncchd.go.jp

© 2017 The Authors. *The Journal of Dermatology* published by John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Pachydermia shows the histopathological findings of dermal edema, mucin deposition, elastic fiber loss, dermal fibrosis and sebaceous gland hyperplasia. Previously, we reported that the degree of these findings is correlated with pachydermia severity.<sup>2</sup> Upon further observation, we found that mast cells were notably infiltrated in the dermis of pachydermia samples.

In this study, pachydermia specimens obtained from six patients with PDP were analyzed. Diagnosis was made according to established clinical and radiological criteria.<sup>3</sup> The study was approved by the ethics committee of the National Center for Child Health and Development and Keio University School

of Medicine. Participants provided written informed consent.

Patient characteristics are summarized in Table S1. All participants were male (age range, 19–51 years). No participant had a family history of PDP. Samples were obtained from the forehead (Fig. 1a) and stained with hematoxylin–eosin (Figs 1b,c, S1), immunohistochemical staining for c-Kit (Figs 1d,e,S1) and toluidine blue (Fig. S1). The number of infiltrated mast cells was calculated by counting and averaging the number of dermal c-Kit-positive cells or toluidine blue metachromatic staining cells in five randomly selected areas using 9400 magnification (Fig. S2). Two samples of normal skin from the forehead of a healthy individual were used as a control (Figs 1e,S1). The slides were independently interpreted by two investigators (K. T. and A. I.) without any knowledge of the clinical data. Any discrepancies in the findings were reconciled by a third investigator (H. N.). The number of dermal c-Kit-positive cells was three- to eightfold higher in pachydermia samples than in controls (Fig. 1f). Increased dermal mast cells were also confirmed by toluidine blue staining, as c-Kit-positive cells may include dermal melanocytes (Fig. S2).

Mast cells are filled with secretory granules containing histamine, protease, cytokines, chemokines and proteoglycans.<sup>4</sup> These granules are released into the extracellular environment by a variety of mechanisms such as immunoglobulin E cross-linking, complement activation and neuropeptide stimulation.<sup>4</sup> A recent report showed that PGE2 can directly activate mast cells to secrete histamine, mediating PGE2-induced vascular permeability.<sup>5</sup> Mast cell degranulation may cause not only dermal edema but also proteoglycan deposition positive for Alcian blue staining; these findings are typically noted in pachydermia.<sup>2</sup> However, the mechanisms of increased mast cells are yet to be clarified, including the role of upregulated PGE2. Nevertheless, we speculate that mast cells are closely associated with the pathobiology of PDP. Further analysis is necessary to reveal the role of mast cells not only in the skin, but also in the other organs of PDP patients.

**ACKNOWLEDGMENT:** This work was supported in part by a grant from the Japanese Ministry of Health, Labor and Welfare (Research for Intractable Diseases) (to H. N.).

**CONFLICT OF INTEREST:** None declared.

Keiji TANESE,<sup>1</sup> Hironori NIIZEKI,<sup>2</sup> Atsuhito SEKI,<sup>3</sup> Kazuhiko NAKABAYASHI,<sup>4</sup> Shinsuke NAKAZAWA,<sup>5</sup> Yoshiki TOKURA,<sup>5</sup> Yuhei KAWASHIMA,<sup>1</sup>

Akiharu KUBO,<sup>1</sup> Akira ISHIKO<sup>6</sup>  
<sup>1</sup>Department of Dermatology, Keio University School of Medicine, Departments of <sup>2</sup>Dermatology, <sup>3</sup>Orthopedics, National Center for Child Health and Development, <sup>4</sup>Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, <sup>5</sup>Department of Dermatology, Hamamatsu University School of Medicine, Shizuoka, and <sup>6</sup>Department of Dermatology, Toho University School of Medicine, Tokyo, Japan

## REFERENCES

- Zhang Z, Xia W, He J *et al.* Exome sequencing identifies *SLCO2A1* mutations as a cause of primary hypertrophic osteoarthropathy. *Am J Hum Genet* 2012; 90: 125–132.
- Tanese K, Niizeki H, Seki A *et al.* Pathological characterization of pachydermia in pachydermoperiostosis. *J Dermatol* 2015; 42: 710–714.
- Sasaki T, Niizeki H, Shimizu A *et al.* Identification of mutations in the prostaglandin transporter gene *SLCO2A1* and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. *J Dermatol Sci* 2012; 68: 36–44.
- Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. *Nat Rev Immunol* 2014; 14: 478–494.
- Morimoto K, Shirata N, Taketomi Y *et al.* Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation. *J Immunol* 2014; 192: 1130–1137.

## SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Figure S1. Figures show the histological features of six pachydermia samples and two normal control samples stained with hematoxylin–eosin staining (original magnification 940), c-KIT (9100) and toluidine blue (9100).

Figure S2. (a) Representative high-powered field (original magnification 9400) microscopic feature of pachydermia sample stained for c-Kit.

Table S1. Summary of the patients analyzed in this study



LETTER TO THE EDITOR

Complete type of pachydermoperiostosis with a novel mutation c.510G>A of the *SLCO2A1* gene

Dear Editor,  
 Pachydermoperiostosis (PDP), or primary hypertrophic osteoarthropathy (PHO; Mendelian Inheritance in Man no. 167100), is a rare genetic disease characterized by finger clubbing, periostosis, pachydermia and cutis verticis gyrata (CVG). Additional symptoms include sebaceous hyperplasia, hyperhidrosis and arthropathy. Two genes, *HPGD* and *SLCO2A1*, are known to be related to PDP and PHO.<sup>1-3</sup> There have been several *SLCO2A1* mutations reported. However, the prevalence of complete type of PDP (clinical triad including CVG) remains largely unknown. Here, we report a case of PDP carrying a novel *SLCO2A1* mutation.

A 37-year-old man was referred to us for finger clubbing and pachydermia. He developed these symptoms at the age of 20 years and noticed oily facial skin and palmoplantar hyperhidrosis at 30 years. On examination, the patient had pachydermia (Fig. 1a), CVG (Fig. 1b) and clubbed fingers (Fig. 1c,d). His parents had no abnormalities in appearance. Radiological examination revealed diaphyseal periostosis of the radius, ulna, tibia and fibula (Fig. 1e). No endocrinosis (growth, thyroid, sexual and adrenal hormones), tumor lesion or hypokalemia was found by blood examination, urinalysis or computed tomography. Gastrointestinal endoscopy showed no abnormality. We diagnosed the patient as having the complete type of PDP.




Figure 1. Clinical findings. (a) Pachydermia on the forehead. (b) Computed tomography of cutis verticis gyrata. (c,d) Digital clubbing. (e) Periostosis of the diaphysis in the radius and ulna. (f) A chromatogram demonstrated the mutations in a family of solute carrier organic anion transporters, member 2A1 (*SLCO2A1*) gene. (g) Pedigree of the family.

Correspondence: Shinsuke Nakazawa, M.D., Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. Email: snakazawa-sin@umin.org

We screened the patient for *SLCO2A1* and *HPGD* mutations, and identified compound heterozygous mutations at c.510G>A and c.1279\_1290del12 in the *SLCO2A1* gene (Fig. 1f). A heterozygous c.510G>A mutation in exon 4 of the *SLCO2A1* gene was novel. This mutation introduces a stop codon at position 170 (p.Trp170\*) and has not been identified until our finding. The proband's mother was heterozygous for c.510G>A (Fig. 1g).

*SLCO2A1* encodes prostaglandin (PG) transporter, and homozygous mutations in *SLCO2A1* cause PHO/PDP. The resultant PG transporter deficiency leads to a high tissue level of PGE2, which contributes to the pathogenesis of PHO/PDP.<sup>1,2</sup> Zhang *et al.*<sup>1</sup> reported that the urinary levels of PGE2 in PHO patients with *SLCO2A1* mutation are significantly higher than those in controls. In this case, the PGE2 level in urine was 83 ng/mmol creatinine (normal, <50).

Eight *SLCO2A1* mutations: c.310G>A (p.G104\*), c.421G>T (p.E141\*), c.765C>T (p.R252\*), c.940+1G>A (p.R288Gfs\*7), c.1040C>T (p.T347I), c.1279\_1290del12 (p.E427\_P430del), c.1668G>C (p.Q556H) and c.1807C>T (p.R603\*) have been thus far confirmed in Japanese PDP patients.<sup>4</sup> However, correlation between the severity of pachydermia and *SLCO2A1* mutational status needs to be confirmed with a greater number of cases.<sup>5</sup>

Here, we first reported a novel mutation c.510G>A of the *SLCO2A1* gene in the complete type of PDP. Our case suggests the genotype-phenotype correlation in *SLCO2A1* as well as the reported cases.

**ACKNOWLEDGMENTS:** This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan to H. N. (Research for Intractable Diseases).

**CONFLICT OF INTEREST:** None declared.

Shinsuke NAKAZAWA,<sup>1,2</sup> Tatsuyoshi MORI,<sup>2,3</sup>  
Hironori NIIZEKI,<sup>4</sup> Kazuhiko  
NAKABAYASHI,<sup>5</sup>  
Yoshiki TOKURA<sup>1</sup>

<sup>1</sup>Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, <sup>2</sup>Division of Dermatology, Fujinomiya City General Hospital, Fujinomiya, <sup>3</sup>Mori Clinic, Mishima, <sup>4</sup>Department of Dermatology, National Center for Child Health and Development, and <sup>5</sup>Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan

## REFERENCES

- 1 Zhang Z, Xia W, He J *et al.* Exome sequencing identifies *SLCO2A1* mutations as a cause of primary hypertrophic osteoarthropathy. *Am J Hum Genet* 2012; 90: 125-132.
- 2 Sasaki T, Niizeki H, Shimizu A *et al.* Identification of mutations in the prostaglandin transporter gene *SLCO2A1* and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. *J Dermatol Sci* 2012; 68: 36-44.
- 3 Nakazawa S, Niizeki H, Matsuda M *et al.* Involvement of prostaglandin E2 in the first Japanese case of pachydermoperiostosis with *HPGD* mutation and recalcitrant leg ulcer. *J Dermatol Sci* 2015; 78: 153-155.
- 4 Niizeki H, Shiohama A, Sasaki T *et al.* The complete type of pachydermoperiostosis: a novel nonsense mutation p. E141\* of the *SLCO2A1* gene. *J Dermatol Sci* 2014; 95: 193-194.
- 5 Tanese K, Niizeki H, Seki A *et al.* Pathological characterization of pachydermia in pachydermoperiostosis. *J Dermatol* 2015; 42: 710-714.